A Pragmatist’s View on Biomarker-Driven Decisions in Oncology: Episode 1
Website: https://www.onclive.comTwitter: https://twitter.com/OncLiveFacebook: https://www.facebook.com/OncLive/LinkedIn: https://www.linkedin.com/company/onc…
Website: https://www.onclive.comTwitter: https://twitter.com/OncLiveFacebook: https://www.facebook.com/OncLive/LinkedIn: https://www.linkedin.com/company/onc…
BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced melanoma after progression on or after a checkpoint inhibitor.
Panelists discuss second-line (2L) treatment strategies for lower-risk myelodysplastic syndrome (LR-MDS), focusing on how to choose a 2L treatment for patients refractory to first-line options,…
Through prolific biomarker research, Fabrice André, MD, PhD, has worked throughout his career to make strides in personalized breast cancer care.
The negative patient-reported effects associated with a CSD result from MCED testing were small and returned to baseline within 12 months for participants with or…
Christina Henson, MD, discussed some of the current imaging guidelines in head and neck cancer, with a focus on extranodal extension.
Acha-Sagredo et al. stratify colorectal cancers using features of an immune-reactive tumor microenvironment. This microenvironment, locally abundant in cytotoxic lymphocytes and antigen-presenting macrophages, facilitates immunotherapy response…
An abstract is unavailable.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in December 2024.
Fox Chase Cancer Center has expanded its genetic counseling and high-risk breast cancer services to Temple Health – Chestnut Hill Hospital.
A new year means new chances to get ahead of your health! Patient advocate Candace Henley and medical oncologist Dr. Cathy Eng join the Tam…